Nevertheless, increased ADA levels were reported in the CSF of a patient affected by autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy (GFAP-A), a rare disease sustained by anti-GFAP antibodies, usually presenting as an acute disorder, characterized by myelitis, abnormal vision, ataxia, altered consciousness, and seizures. Here, ADA is linked to myelitis.